CCL5 and neoplasm: Furthermore, CCL5 positivity in TCs was associated with a 1.55-fold, 1.81-fold, 1.65-fold, and 2.60-fold increased risk of tumor-associated death for patients with tumor stage pT3 + 4, nodal stage N0, patients without chemotherapy or tumors of the luminal molecular subtype, respectively.